Published

A review of psychedelics trials completed in depression, informed by European regulatory perspectives.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience applied
Date: 2025-01-01
Source: PubMed
DOI: 10.1016/j.nsa.2025.105516
PubMed: 40654583

Authors

Silva F Butlen-Ducuing F Guizzaro L Balabanov P

Watch author

Derived topics and classifications

psilocybin Depression Clinical Trial Review Article Treatment-Resistant Depression Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols2026-04-01 A review of psychedelics trials completed in depression, informed by European regulatory perspectives.2025-01-01

Related papers

From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERSInternational Journal of Innovative Technologies in Social Science · 2026-01-22 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01 Psychedelics’ Use as Medicine Hits Significant RoadblockPsychiatric News · 2024-06-12 Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological DistressWestern CEDAR (Western Washington University) · 2018-01-01 Narrative therapy-assisted psilocybin use for treatment of depressionSeattle Pacific University Research Conference · 2017-01-01